MO SB1581

Creates a grant program through the Department of Health and Senior Services to fund FDA-overseen clinical trials on ibogaine for treating opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions

Requires grant recipients to be Missouri-based entities with proven neurological research expertise, neurosurgery programs with cardiac intensive care capabilities, and partnership agreements with multistate consortiums that have filed FDA investigational new drug applications

Establishes matching fund requirements where grant recipients must secure equal funding from non-state sources before receiving state disbursements

Creates two dedicated state treasury funds: the "Ibogaine Study Fund" for grant awards and the "Ibogaine Intellectual Property Fund" to capture revenues from any resulting patents or commercial rights, with IP fund proceeds designated for veterans and at-risk populations

Restricts ibogaine prescribing to licensed physicians and requires supervised administration at hospitals or licensed health care facilities, effective only upon FDA approval of ibogaine for medical use; grant applications must begin by November 1, 2026